Browse our 650+ Publications
Latest Publications
HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis
Poonia et al.
Scientific Reports
October 2018
Authors and Affiliates
Bhawna Poonia,1 Natarajan Ayithan,1 Madhuparna Nandi,1 Henry Masur,2 and Shyam Kottilil1
1Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201 USA
2Critical Care Medicine Department, NIH Clinical Center, Bethesda, MD 20892 USA
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
Mansfield et al.
Journal of Thoracic Oncology
October 2018
Authors and Affiliates
Mansfield AS1, Peikert T2, Smadbeck JB3, Udell JBM4, Garcia-Rivera E5, Elsbernd L6, Erskine CL6, Van Keulen VP6, Kosari F3, Murphy SJ3, Ren H7, Serla VV3, Schaefer Klein JL3, Karagouga G3, Harris FR3, Sosa C3, Johnson SH3, Nevala W6, Markovic SN1, Bungum AO2, Edell ES2, Dong H8, Cheville JC7, Aubry MC7, Jen J9, Vasmatzis G10
1 Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
2 Division of Pulmonary Medicine and Critical Care, Mayo Clinic, Rochester, Minnesota.
3 Center for Individualized Medicine, Biomarker Discovery Group, Mayo Clinic, Rochester, Minnesota.
4 Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
5 nference, Cambridge, Massachusetts.
6 Department of Immunology, Mayo Clinic, Rochester, Minnesota.
7 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
8 Department of Immunology, Mayo Clinic, Rochester, Minnesota; Department of Urology, Mayo Clinic, Rochester, Minnesota.
9 Medical Genome Facility, Mayo Clinic, Rochester, Minnesota.
10 Center for Individualized Medicine, Biomarker Discovery Group, Mayo Clinic, Rochester, Minnesota. Electronic address: vasmatzis.george@mayo.edu
High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata
De Jong et al.
JCI Insight
October 2018
Authors and Affiliates
de Jong A1, Jabbari A1, Dai Z1, Xing L2, Lee D1, Li MM1, Duvic M3, Hordinsky M4, Norris DA5, Price V6, Mackay-Wiggan J1, Clynes R1, Christiano AM1,7
1 Department of Dermatology and.
2 Department of Pathology, Columbia University, New York, New York, USA.
3 Department of Dermatology, MD Anderson Cancer Center, Houston, Texas, USA.
4 Department of Dermatology, University of Minnesota, Minneapolis, Minnesota, USA.
5 Department of Dermatology, University of Colorado, Denver, Colorado, USA.
6 Department of Dermatology, UCSF, San Francisco, California, USA.
7 Department of Genetics and Development, Columbia University, New York, New York, USA.
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy
Yossef et al.
JCI Insight
October 2018
Authors and Affiliates
Yossef R1, Tran E1,2, Deniger DC1, Gros A1,3, Pasetto A1, Parkhurst MR1, Gartner JJ1, Prickett TD1, Cafri G1, Robbins PF1, Rosenberg SA
1 Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.
2 Earle A. Chiles Research Institute and the Providence Portland Medical Center, Portland, Oregon, USA.
3 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Pg. Vall d'Hebron, Barcelona, Spain.
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Ruella et al.
Nature Medicine
October 2018
Authors and Affiliates
Ruella M1,2,3,4,5, Xu J1,2,3, Barrett DM6, Fraietta JA1,2,3,4, Reich TJ1, Ambrose DE1, Klichinsky M1,7, Shestova O1, Patel PR1, Kulikovskaya I1, Nazimuddin F1, Bhoj VG1,2,3, Orlando EJ8, Fry TJ9, Bitter H8, Maude SL6, Levine BL1,2,3, Nobles CL10, Bushman FD10, Young RM1, Scholler J1, Gill SI1,3,5, June CH11,12,13,14, Grupp SA6, Lacey SF1,2,3, Melenhorst JJ15,16,17.
1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
2
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
3
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
4
Parker Institute for Cellular Immunotherapy at the University of Pennsylvania, Philadelphia, PA, USA.
5
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
6
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
7
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
8
Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
9
University of Colorado, Children's Hospital Colorado, Denver, CO, USA.
10
Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
11
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
12
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
13
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
14
Parker Institute for Cellular Immunotherapy at the University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
15
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
16
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
17
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria et al.
Nature Medicine
Papers
October 2018
Authors and Affiliates
Rodabe N. Amaria1, Sangeetha M. Reddy2, Hussein A. Tawbi1, Michael A. Davies1, Merrick I. Ross3, Isabella C. Glitza1, Janice N. Cormier3, Carol Lewis4, Wen-Jen Hwu1, Ehab Hanna4, Adi Diab1, Michael K. Wong1, Richard Royal3, Neil Gross4, Randal Weber4, Stephen Y. Lai4, Richard Ehlers3, Jorge Blando5, Denái R. Milton6, Scott Woodman1, Robin Kageyama7, Danny K. Wells7, Patrick Hwu1, Sapna P. Patel1, Anthony Lucci3, Amy Hessel4, Jeffrey E. Lee3, Jeffrey Gershenwald3, Lauren Simpson1, Elizabeth M. Burton3, Liberty Posada1, Lauren Haydu3, Linghua Wang8, Shaojun Zhang8, Alexander J. Lazar 9, Courtney W. Hudgens 9, Vancheswaran Gopalakrishnan3, Alexandre Reuben3, Miles C. Andrews3, Christine N. Spencer8, Victor Prieto9, Padmanee Sharma5,10, James Allison5, Michael T. Tetzlaff9,11 and Jennifer A. Wargo3,8
1Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 2Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 3Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 4Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA. 5Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA. 6Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA. 7Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. 8Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA. 9Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA. 10Department of Genitourinary Cancers, MD Anderson Cancer Center, Houston, TX, USA. 11Department of Translational and Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA.
CD4+T cells mediate protection against Zika associated severe disease in a mouse model of infection
Hassert et al.
Papers
PLOS Pathogens
September 2018
Authors and Affiliates
Mariah Hassert1, Kyle J. Wolf1, Katherine E. Schwetye2, Richard J. DiPaolo1, James D. Brien1, Amelia K. Pinto1
1Department of Molecular Microbiology and Immunology, Saint Louis University, St Louis, Missouri, United States of America, 2Department of Pathology, Saint Louis University, St. Louis, Missouri, United States of America
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson et al.
Nature Communications
Papers
September 2018
Authors and Affiliates
K.G. Paulson1,2,3, V. Voillet2, M.S. McAfee2, D.S. Hunter2, F.D. Wagener2, M. Perdicchio2,6, W.J. Valente2, S.J. Koelle1,2, C.D. Church1, N. Vandeven1, H. Thomas1, A.G. Colunga1, J.G. Iyer1, C. Yee4, R. Kulikauskas1, D.M. Koelle1,2,5, R.H. Pierce2, J.H. Bielas1,2, P.D. Greenberg1,2, S. Bhatia1,2,3, R. Gottardo1,2, P. Nghiem1,2,3 & A.G. Chapuis1,2,3
1University of Washington, Seattle, WA, USA. 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3Seattle Cancer Care Alliance, Seattle, WA, USA. 4MD Anderson Cancer Center, Houston, TX, USA. 5Benaroya Research Institute, Seattle, WA, USA.
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Jelcic et al.
Papers
September 2018
Authors and Affiliates
Ivan Jelcic,1 Faiez Al Nimer,1,2 Jian Wang,1 Verena Lentsch,1 Raquel Planas,1 Ilijas Jelcic,1 Aleksandar Madjovski,1 Sabrina Ruhrmann,2 Wolfgang Faigle,1 Katrin Frauenknecht,3 Clemencia Pinilla,4 Radleigh Santos,5 Christian Hammer,6,7 Yaneth Ortiz,1 Lennart Opitz,8 Hans Gronlund,9 Gerhard Rogler,10 Onur Boyman,11 Richard Reynolds,12 Andreas Lutterotti,1 Mohsen Khademi,2 Tomas Olsson,2 Fredrik Piehl,2 Mireia Sospedra,1 and Roland Martin1
1Neuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, 8091 Zurich, Switzerland 2Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, 17176 Stockholm, Sweden 3Institute of Neuropathology, University of Zurich, University Hospital Zurich, 8091 Zurich, Switzerland 4Torrey Pines Institute for Molecular Studies (TPIMS), San Diego, CA, USA 5Torrey Pines Institute for Molecular Studies (TPIMS), Port St. Lucie, FL, USA 6School of Life Sciences, E cole Polytechnique Federale de Lausanne, 1015 Lausanne, Switzerland 7Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland 8Functional Genomics Center Zurich, Swiss Federal Institute of Technology and University of Zurich, 8057 Zurich, Switzerland 9Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, 17176 Stockholm, Sweden 10Department of Gastroenterology and Hepatology, University of Zurich, University Hospital Zurich, 8091 Zurich, Switzerland 11Department of Immunology, University of Zurich, University Hospital Zurich, 8091 Zurich, Switzerland 12Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK